Together with already large pharmaceutical markets such as Japan, it is not difficult to see why Asia represents a block of great interest to global pharmaceutical giants. But what of the biotechnology industry? Should it participate moreactively as Asia develops? Can it afford not to? This article addresses issues to consider for biotechnology companies contemplating an Asia strategy as part of planning product development.
Novotech Publishes Multi-Specific Monoclonal Antibodies Global Clinical Trial Landscape Report
Singapore - Novotech, the leading Asia Pacific centred biotech CRO has publishedRead more